A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Tolerability, and Safety of Celecoxib Oral Solution (ELYXYB) in Acute Treatment of Episodic Migraine With or Without Aura

Richard B Lipton
Albert Einstein College of Medicine

Sagar Munjal (smunjal@drreddys.com)
Dr. Reddy's Laboratories Ltd.  https://orcid.org/0000-0001-5387-720X

Stewart J Tepper
Dartmouth College Geisel School of Medicine

Charles Iaconangelo
Pharmerit North America LLC

Daniel Serrano
Pharmerit North America LLC

Research article

Keywords: [3-10] Cyclooxygenase 2 Inhibitors, migraine disorders, non-steroidal, anti-inflammatory agents, clinical trial, phase III.

Posted Date: June 2nd, 2021

DOI: https://doi.org/10.21203/rs.3.rs-553656/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background

Safe, effective, oral therapies are needed for acute treatment of migraine. This clinical trial assessed the efficacy, tolerability, and safety of celecoxib oral solution (ELYXYB) in a single migraine attack associated with moderate-to-severe pain.

Methods

This Phase III, randomized, double-blind, placebo-controlled, multicenter trial treated adults with episodic migraine (with or without aura) with a single 4.8 mL dose of 120-mg celecoxib oral solution or placebo. Co-primary endpoints were the proportion of patients who were pain-free and free from the most bothersome migraine symptom (MBS) at 2 hours post-dose. The MBS was identified at screening from among nausea, photophobia, or phonophobia.

Results

Six hundred thirty-one patients were randomized (mean age 41 years, range 18–75; 84.3% female). One study site met prespecified outlier criteria and was excluded from efficacy analyses. This site had a mean 2-hour pain freedom placebo response rate of 75% vs 23.5% for all other sites. In subsequent analysis, 2-hour post-dose pain freedom response rates were significantly higher in the celecoxib oral solution group vs placebo (32.8%, [27.2%, 38.8%]) vs 23.5%, [18.5%, 29.2%]; \( P = 0.020 \)). For 2-hour post-dose MBS freedom, response rates were significantly higher in the celecoxib oral solution group vs placebo (58.1% [51.4%, 64.5%] vs 43.9% [37.2%, 50.7%]; \( P = 0.003 \)). A total of 10.7% (31/289) of patients treated with celecoxib oral solution and 9.9% (28/283) of placebo-treated patients reported a treatment-emergent adverse event (TEAE). Study drug-related TEAEs were reported by 7.3% (21/289) and 7.4% (21/283) of celecoxib oral solution and placebo patients, respectively; the most common were nausea (celecoxib oral solution: 1.4% [4/289] vs placebo: 1.8% [5/283]) and dysgeusia (celecoxib oral solution: 1.7% [5/289] vs placebo: 1.1% [3/283]). No serious TEAEs, deaths, or drug-related TEAEs leading to withdrawal were reported.

Conclusions

Celecoxib oral solution is a safe, effective COX-2-selective nonsteroidal anti-inflammatory drug for the treatment of acute migraine. In this analysis, celecoxib oral solution was significantly more effective than placebo and was also associated with a low rate of gastric TEAEs. Celecoxib oral solution may provide a convenient, alternate option to currently available treatments.
Trial registration:
ClinicalTrials.gov Identifier: NCT03009019; Registered January 4, 2017; Retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT03009019

Background
Migraine is a common neurologic disorder associated with disabling headache requiring acute treatment [1], and estimated to affect between 17.1% and 20.7% of females and between 5.6% and 9.7% of males in the United States [2, 3]. Beyond headache pain, the most prevalent symptoms of migraine include light sensitivity (photophobia), sound sensitivity (phonophobia), and nausea [1, 4–6]. Other common symptoms include hyperalgesia (an increased sensitivity to painful stimuli) and cutaneous allodynia (dermal pain provoked by non-painful stimuli) [7].

Key clinical research and expert guidance recommend the early acute treatment of migraine via targeted medications administered shortly after the headache begins [8, 9]. The primary goal of treatment is to safely and quickly achieve freedom from migraine pain and symptoms, without recurrence. However, as migraine severity and characteristics vary, patients typically require individualized approaches to achieve success [8]. Triptans are the mainstay of acute treatment of migraine and are available in several formulations [10]. Oral triptans have a relatively slow rate of absorption, and a corresponding lag in onset of action, which can result in delayed pain relief [11]. Liquid triptan nasal sprays are more rapid-acting than oral triptans, but conventional intranasal spray pumps deposit only a limited amount of drug to the upper posterior nasal cavity; a substantial amount of the dose is swallowed. Once swallowed, the triptan effectively becomes an orally administered medication subject to the previously noted disadvantages [12]. Sumatriptan subcutaneous injections have a more rapid onset of action than oral triptans, but also have lower tolerability and patient acceptance [13, 14]. Other drugs, such as opioids, have been shown effective in treating migraine headache [1, 8], but have high adverse event (AE) rates [15–17], and are not recommended as regular [1] or first-line therapy [18], in part because they are risk factors for the development of chronic migraine [19].

Some patients with migraine respond well to simple pain relievers [1]. For example, nonsteroidal anti-inflammatory drugs (NSAIDs) have analgesic, antipyretic, and anti-inflammatory effects [20]. Several NSAIDs, including diclofenac, ibuprofen, and naproxen, are established as effective in migraine and are recommended treatment options for acute attacks [1]. These non-selective NSAIDs inhibit the biosynthesis of prostaglandins (which play a key role in migraine pathogenesis) [21] through two isoenzymes, cyclooxygenase (COX)-1 and COX-2. However, it is common for patients to experience gastrointestinal (GI) AEs with non-selective NSAIDs. These problems primarily involve GI bleeding and ulcers, which are related to COX-1 inhibition; however, the analgesic efficacy of NSAIDs is associated with COX-2 inhibition [20]. Since migraine is a chronic condition [10] requiring episodic treatment [8, 9], it is also important to recognize that the cumulative consumption of non-selective NSAIDs can lead to serious AEs, including GI, cardiovascular, and renal events [22]. Predicated on this, the use of COX-2-selective
versus non-selective NSAIDs may provide a therapeutic advantage in the acute management of migraine [20].

Celecoxib is a COX-2 selective NSAID with an analgesic profile similar to that of other NSAIDs [23, 24]. A systematic review and meta-analysis of celecoxib capsules in osteoarthritis and rheumatoid arthritis found a significantly reduced incidence of GI AEs with celecoxib capsules compared to non-specific NSAIDs such as naproxen, as well as the COX-2-specific NSAID, rofecoxib [23]. In 2007, Loo and colleagues evaluated 400-mg celecoxib capsules versus 550-mg naproxen sodium in an open-label, randomized, controlled study (N = 60) for acute treatment of patients with migraine. Celecoxib capsules showed similar pain reduction as naproxen, based on Visual Analogue Scale results, as well as significantly reduced gastric pain incidence [25]. However, celecoxib capsules have not been approved for acute treatment of migraine in the U.S [26].

ELYXYB (celecoxib oral solution, 25 mg/mL, previously known as DFN-15) is a new liquid formulation of celecoxib, approved in May 2020 for the acute treatment of migraine with or without aura in adults [27]. It has a shorter demonstrated time to maximal concentration (T_{max}) than available celecoxib capsule formulations [28] and has been evaluated and found effective versus placebo in a randomized, double-blind, placebo-controlled trial of patients with episodic migraine (N = 622). At 2 hours post-dose, celecoxib oral solution was significantly superior to placebo for the co-primary endpoints of pain freedom (35.6% vs 21.7%; P < 0.001) and freedom from the most bothersome symptom (MBS) (57.8% vs 44.8%; P = 0.007) [26]. The second pivotal Phase III study, reported here, was conducted to verify the efficacy and safety of celecoxib oral solution.

**Methods**

**Study design**

This was a randomized controlled study with two double-blind (DB) treatment periods, conducted at 41 U.S. centers. Patients were randomized 1:1 to receive the following: celecoxib oral solution (120 mg/4.8 mL celecoxib, liquid formulation with celecoxib 25 mg/mL) or matching placebo (0 mg/4.8 mL). The total duration of participation was up to 10 weeks from baseline. Before study initiation, the research protocol, patient information and informed consent form, and other relevant study documentation were reviewed and approved by the Institutional Review Boards for each study center.

In the first DB period, a single migraine attack, associated with moderate-to-severe pain, was treated as soon as possible (ie, within ≤ 1 hour). Treatment was only to be used for a new attack, not a recurrence, and ≥ 48 hours of freedom from pain and symptoms due to a previous migraine attack was required. In the second DB period, a single migraine attack, associated with any pain level, was treated a soon as possible. Only results for the first DB period are reported here.
Patients used an electronic diary (eDiary) to record all pre-dose and post-dose efficacy data. This included migraine date and time, aura information, last food intake and fat content, pre-dose pain and functioning levels, and MBS data. Patients also recorded the following information: time to meaningful pain relief and pain freedom; post-dose pain levels and PPMQ-R; and treatment satisfaction, all measured at predefined time points. Following treatment, patients had the option to take rescue medication after the 2-hour post-dose timepoint. Rescue medication selection was determined by the investigator and participant, and was exclusive of study-prohibited medications. Patients returned to the study site within 2 to 7 days of treatment.

**Study Patients**

Patients were required to be previously diagnosed with episodic migraine, with or without aura, as defined by International Classification of Headache Disorders, 3rd edition (ICHD-3), and to have had the diagnosis for ≥ 1 year. Additional inclusion criteria were as follows: male or female, aged 18 to 75 years; migraine onset prior to 50 years of age; history of episodic migraine (ICHD-3) with 2–8 monthly attacks (with or without aura), ≤ 14 headache days per month, and ≥ 48 hours of headache-free time between attacks; reported usual migraine pain (without treatment) of 2 (moderate) or 3 (severe) on headache pain severity scale (range 0–3); able to differentiate between migraine and a tension-type or cluster headache; if female and of childbearing potential, a negative pregnancy test was required at all study visits; female patients were required not to be lactating, not to be planning to become pregnant, and to practice reliable birth control or abstinence throughout the study. Participants had to read, speak, and understand English proficiently, to provide written, informed consent, and to be willing and, in the opinion of the investigator, able to comply with study procedures and scheduling.

Exclusion criteria were as follows: prior exposure to celecoxib oral solution; intolerance to any celecoxib or sulfonamide formulation, or significant AEs or contraindications related to other NSAIDs (eg, due to gastrointestinal bleed, ulcer, or history of acute renal failure); treatment with an investigational drug or device within 30 days of randomization, or participation in a central nervous system clinical trial within 2 months of randomization. Patients were also excluded if they had experienced medication overuse in the 90 days before screening, defined as opioids or combination medications, including barbiturates, used ≥ 10 days; NSAIDs or other simple medications (such as over the counter medications) > 14 days per month; and triptans or ergots ≥ 10 days per month. Alcohol or substance use disorder identified within 12 months of screening, a positive urine drug screen for recreational drugs or alcohol, or prescription drug use not explained by disclosed concomitant medication use also excluded patients from participation.

Patients with a history of the following drug treatments were also excluded: onobotulinum toxin A for migraine in the 4 months before screening (cosmetic use was acceptable); unstable dosage of migraine prophylactic medication use in the 30 days before and/or throughout screening; use of mini-prophylaxis for menstrual migraine; history of cluster headaches, or only a “probable migraine” diagnosis (per ICHD-3); history of cerebrovascular events, including but not limited to stroke or transient ischemic attack; chronic use of warfarin sodium or an equivalent drug; current antipsychotic use, or use within 30 days of randomization; treatment with cytochrome P450 (CYP)2C9 inducers, or with CYP2D6 substrates with a
narrow therapeutic window (ie, thioridazine), within 7 days of randomization. Patients with the following medical conditions were excluded: concurrent seizure disorder or history of migralspsy (seizure following migraine); history of ischemic coronary artery disease or congenital heart disease; insulin-requiring diabetes mellitus or diabetes with A1C > 7.9%; positive screening test for human immunodeficiency virus, hepatitis B surface antigen, or hepatitis C virus antibody; history of cancer within the past 5 years, except adequately treated basal cell or squamous cell skin carcinoma, or in situ cervical cancer; any medical condition or procedure that, in the judgment of the investigator, would have confounded the study objectives. Last, patients with the following vital signs or laboratory values were excluded: Uncontrolled hypertension or screening systolic/diastolic blood pressure (SBP/DBP) > 140/90 mm hg; Fridericia’s corrected QT interval > 450 msec, serum creatinine > 1.5x upper limit of normal (ULN), and/or serum total bilirubin > 1.5x ULN; serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), or alkaline phosphate > 2.5x ULN; or, any clinical laboratory or electrocardiogram (ECG) abnormality that could endanger the participant or interfere with study conduct.

Patients could be withdrawn subsequent to randomization if they became pregnant, violated any protocol requirements affecting study outcomes, developed significant illness, needed to undergo major acute surgery, or if the investigator deemed it unsafe for the participant to continue in the study. Patients could also be excluded if they took rescue medication before data collection at the 2-hour post-dose timepoint.

**Study procedures**

During the screening visit, all patients received a full physical exam, 12-lead electroencephalogram, and had their vital signs and blood pressure checked. In addition, a migraine history assessment was used to determine the participant’s MBS (nausea, photophobia, or phonophobia) associated with migraine. Patients attended two subsequent study visits: at baseline (randomization) and following treatment. At study randomization, patients were provided with single dose bottles with a deliverable volume of 4.8 mL and were instructed to drink the entire contents during the treated migraine attack. At study visit, patients were required to return all unused drug, and their eDiary was checked for treatment compliance.

This study was performed in compliance with International Council for Harmonisation Good Clinical Practices, as well as the ethical principles of the Declaration of Helsinki and the U.S. Food and Drug Administration (FDA) Code of Federal Regulations. All patients provided written informed consent.

**Efficacy assessments**

The co-primary endpoints comparing celecoxib oral solution to placebo were the proportion of patients who were pain-free at 2 hours post-dose (defined as a reduction from pre-dose moderate [Grade 2] or severe [Grade 3] pain to none [Grade 0]) and the proportion of patients reporting freedom from their screening MBS (among nausea, photophobia, or phonophobia). The selection of co-primary endpoints was based on the most current guidance from the FDA for clinical trials in migraine [29].

In addition, a secondary endpoint was participant treatment satisfaction as measured by total, total raw, subscale, and global scores on the Patient Perception of Migraine Questionnaire-Revised (PPMQ-R) at 24
hours post-dose. The PPMQ-R is a validated instrument of 30 questions used to assess satisfaction with migraine medication. PPMQ-R subscales measure efficacy (11 questions), function (4 questions), ease of use (2 questions), and side effects (10 questions); and also includes 3 global questions measuring medication effectiveness, side effects, and overall satisfaction [30]. Since patients did not pay for the study drug, the 2 PPMQ-R questions in the drug cost subscale were not included. Items were scored on a 7-point scale from 1 (very satisfied) to 7 (very dissatisfied), except items related to tolerability, which were scored on a 5-point scale from 1 (not at all) to 5 (extremely).

Other secondary endpoints included the proportion of patients free from nausea, photophobia, and phonophobia at 15, 30, and 45 minutes and 1, 1.5, 2, 4, and 24 hours post-dose; the proportion of patients with pain relief at 15, 30, and 45 minutes and 1, 1.5, 2, 4, and 24 hours post-dose; and the proportion of patients with sustained pain relief. Sustained pain relief was defined as pain-free at 2 hours post-dose, with no use of rescue medication and no recurrence of headache pain within 2 to 24 hours post-dose.

**Safety and tolerability assessments**

Safety assessments included the following: AEs from screening until study completion or discontinuation; compliance with study drug use; rescue medication use; concomitant medication review; physical examinations and suicidality check; pregnancy tests, as applicable; vital signs (sitting SBP/DBP, pulse rate, and body temperature); laboratory examinations (hematology, chemistry, and urinalysis); and 12-lead ECGs.

**Statistical analysis**

Descriptive statistical methods were used to summarize study data, with sample size and hypothesis testing performed for the co-primary and secondary efficacy endpoints. For the first and second co-primary endpoint, respectively, a sample size of 600 patients was estimated to provide 88% power and 480 patients provided 94% power to detect the assumed difference between placebo and celecoxib oral solution (11.6% and 16.5% for the first and second co-primary endpoints, respectively), and anticipating a 15% dropout rate. Comparisons between the celecoxib oral solution and placebo groups for all efficacy endpoints were conducted using the full analysis set (FAS). The FAS included all randomized patients who took $\geq 1$ dose of study drug and had $\geq 1$ post-baseline assessment for symptoms or pain. Missing efficacy data were imputed using last observation carried forward (LOCF), with results provided for LOCF and observed case (OC) data. The safety set included all patients who received $\geq 1$ dose of study drug (recorded in their eDiary). Unless otherwise specified, all statistical testing and confidence intervals (CIs) were 2-sided and performed using a significance level of 0.05.

For both co-primary endpoints, a closed sequential procedure using Fisher’s exact test was used to test significance. If the first co-primary endpoint was statistically significant, the second co-primary endpoint was tested for statistical significance. To be included in the analysis of the second co-primary endpoint, patients must have experienced their screening MBS symptom pre-dose (but it did not have to be designated as their pre-dose MBS). Patients who did not report MBS at screening, did not have their screening MBS present at pre-dose, who took rescue medication prior to data collection at the 2-hour
post-dose timepoint, and/or who had a Grade 1 (mild) pre-dose pain levels were excluded from analysis. The number of patients with response and with non-missing assessments, and the proportion of responders in the celecoxib oral solution and placebo groups, were calculated (including corresponding 95% CIs, odds ratios, and \( P \)-values). Exploratory subgroup analyses on the co-primary endpoints were conducted in the FAS using the following baseline categories: age (18–34 years, 35–49 years, 50–64 year and \( \geq 65 \) years); sex (male and female); and ethnicity (Hispanic and non-Hispanic). For each subgroup, the odds ratio for response and corresponding CI for each co-primary endpoint was calculated using the treatment group, the subgroup variable, and the treatment-by-subgroup interaction term as covariates in the logistic regression model.

The secondary efficacy endpoint of PPMQ-R treatment satisfaction at 24 hours post-dose was compared between the celecoxib oral solution and placebo groups using Wilcoxon rank-sum testing. PPMQ-R scores at 24 hours post-dose were also compared to baseline scores (which assessed the patients’ usual migraine medication pre-study) for celecoxib oral solution patients only. The proportion of responders for the additional secondary efficacy endpoints were summarized by treatment group, and corresponding \( P \)-values from Fisher’s exact test were computed for between-group comparisons.

Last, based on a prespecified post-hoc analysis plan, case diagnostics were used to evaluate the strength of any site-specific influence on estimates. A logistic generalized linear mixed-effects model (GLMM) was used to detect potential site outliers, as follows: a GLMM was fit with treatment arm as the fixed-effect predictor and site as the random-effect predictor; next, outlier detection statistics were computed, including Cook’s distance and the covariance ratio [31]. The Cook’s distance statistic evaluated how much the treatment effect estimate changed when each site was removed from the analysis sample. The covariance ratio statistic evaluated change in the treatment effect CI when each site was removed from the analysis sample. A site was considered an outlier if it led to a Cook’s distance or covariance ratio value that was at least twice as large as all other sites. This was more rigorous than the typical cut-off value of \( 4/n \) for Cook’s distance [32], where \( n \) would be the number of sites (40), which would have yielded a liberal cut-off value of 0.10 for defining an outlier. These conservative criteria were applied to ensure that any site identified as an outlier would be aberrant and influential. If any outlier sites were identified, they were to be removed from the analysis sample. Finally, the primary endpoints were recomputed by conducting the pre-specified analysis (Fisher’s exact test with LOCF imputation) using the modified analysis sample.

All statistical analyses were conducted using the SAS® software package (version 9.3) or R statistical software (version 3.4.4).

Results

Patients
A total of 926 patients were screened; 631 (68.1%) met entry criteria and were subsequently randomized (Fig. 1). Patient demographics and baseline characteristics are summarized in Table 1; mean patient age was 41 years (range 18 to 75), and the majority were female (487 [84.3%]), non-Hispanic (493 [85.3%]), and white (426 [73.7%]). A total of 544 of 631 patients (86.2%) completed the treatment period, with 81 (12.8%) discontinuing. The primary reasons for discontinuation are detailed in Fig. 1. Additionally, 6 randomized patients were recorded as not having taken any drug (celecoxib oral solution or placebo) and were excluded from the efficacy and safety analyses. The FAS comprised 567 of 631 (89.9%) randomized patients, including 287 in the celecoxib oral solution arm and 280 in the placebo arm. The safety set included 572 of 631 (90.6%) randomized patients, including 289 in the celecoxib oral solution arm and 283 in the placebo arm.
Table 1
Demographics and Baseline Characteristics (Safety Set)

<table>
<thead>
<tr>
<th>Mean (SD) unless otherwise noted</th>
<th>Placebo n = 283</th>
<th>Celecoxib oral solution n = 289</th>
<th>Overall N = 578</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age, years</strong></td>
<td>40.4 (13.0)</td>
<td>41.4 (14.0)</td>
<td>41.0 (13.4)</td>
</tr>
<tr>
<td><strong>Sex, n (%)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>38 (13.4)</td>
<td>52 (18.0)</td>
<td>91 (15.7)</td>
</tr>
<tr>
<td>Female</td>
<td>245 (86.6)</td>
<td>237 (82.0)</td>
<td>487 (84.3)</td>
</tr>
<tr>
<td><strong>Ethnicity, n (%)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hispanic or Latino</td>
<td>41 (14.5)</td>
<td>40 (13.8)</td>
<td>83 (14.4)</td>
</tr>
<tr>
<td>Not Hispanic or Latino</td>
<td>241 (85.2)</td>
<td>248 (85.8)</td>
<td>493 (85.3)</td>
</tr>
<tr>
<td>Not reported</td>
<td>1 (0.4)</td>
<td>1 (0.3)</td>
<td>2 (0.3)</td>
</tr>
<tr>
<td><strong>Race, n (%)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asian</td>
<td>3 (1.1)</td>
<td>1 (0.3)</td>
<td>4 (0.7)</td>
</tr>
<tr>
<td>Black or African American</td>
<td>63 (22.3)</td>
<td>64 (22.1)</td>
<td>130 (22.5)</td>
</tr>
<tr>
<td>White</td>
<td>209 (73.9)</td>
<td>214 (74.0)</td>
<td>426 (73.7)</td>
</tr>
<tr>
<td>Other</td>
<td>8 (2.8)</td>
<td>10 (3.5)</td>
<td>18 (3.1)</td>
</tr>
<tr>
<td><strong>Weight (kg)</strong></td>
<td>83.4 (21.5)</td>
<td>83.1 (21.2)</td>
<td>83.3 (21.3)</td>
</tr>
<tr>
<td><strong>BMI (kg/m²)</strong></td>
<td>30.4 (7.4)</td>
<td>30.0 (7.3)</td>
<td>30.2 (7.4)</td>
</tr>
<tr>
<td><strong>Current smoking or use of nicotine containing products status, n (%)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Current user</td>
<td>32 (11.3)</td>
<td>27 (9.3)</td>
<td>59 (10.2)</td>
</tr>
<tr>
<td>Former user</td>
<td>36 (12.7)</td>
<td>50 (17.3)</td>
<td>87 (15.1)</td>
</tr>
<tr>
<td>Never used</td>
<td>215 (76.0)</td>
<td>212 (73.4)</td>
<td>432 (74.7)</td>
</tr>
<tr>
<td><strong>Current smoker or nicotine product users</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Years of use</td>
<td>18.3 (12.2)</td>
<td>14.9 (11.9)</td>
<td>16.8 (12.1)</td>
</tr>
<tr>
<td>Age at migraine onset (years)</td>
<td>22.1 (11.0)</td>
<td>21.4 (10.7)</td>
<td>21.8 (10.9)</td>
</tr>
<tr>
<td><strong>Migraine with aura, n (%)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>169 (59.7)</td>
<td>152 (52.6)</td>
<td>325 (56.2)</td>
</tr>
</tbody>
</table>

BMI, body mass index; SD, standard deviation.
Mean (SD) unless otherwise noted

<table>
<thead>
<tr>
<th></th>
<th>Placebo n = 283</th>
<th>Celecoxib oral solution n = 289</th>
<th>Overall N = 578</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n (%)</td>
<td>n (%)</td>
<td>n (%)</td>
</tr>
<tr>
<td>No</td>
<td>114 (40.3)</td>
<td>136 (47.1)</td>
<td>252 (43.6)</td>
</tr>
<tr>
<td>Experience migraine-associated symptoms, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nausea</td>
<td>247 (87.3)</td>
<td>253 (87.5)</td>
<td>506 (87.5)</td>
</tr>
<tr>
<td>Photophobia</td>
<td>275 (97.2)</td>
<td>275 (95.2)</td>
<td>556 (96.2)</td>
</tr>
<tr>
<td>Phonophobia</td>
<td>248 (87.6)</td>
<td>254 (87.9)</td>
<td>508 (87.9)</td>
</tr>
<tr>
<td>Vomiting</td>
<td>117 (41.3)</td>
<td>152 (52.6)</td>
<td>273 (47.2)</td>
</tr>
<tr>
<td>Osmophobia</td>
<td>162 (57.2)</td>
<td>146 (50.5)</td>
<td>310 (53.6)</td>
</tr>
<tr>
<td>Skin sensitivity</td>
<td>79 (27.9)</td>
<td>83 (28.7)</td>
<td>165 (28.5)</td>
</tr>
<tr>
<td>Worsening with movement or exertion</td>
<td>273 (96.5)</td>
<td>271 (93.8)</td>
<td>550 (95.2)</td>
</tr>
</tbody>
</table>

BMI, body mass index; SD, standard deviation.

**Primary full analysis set findings**

Response rates for the co-primary endpoint of headache pain freedom at 2 hours post-dose (LOCF, 95% CI) was 32.9% (27.4%, 38.7%) in the celecoxib oral solution group and 25.8% (20.7%, 31.5%) in the placebo group \((P = 0.075)\). For the co-primary endpoint of 2-hour MBS freedom, response rates (LOCF, 95% CI) in the celecoxib oral solution group were 58.9% (52.4%, 65.2%) and 45.0% (38.5%, 51.7%) in the placebo group \((P = 0.003)\) (Supplemental Table 1). The pre-specified post-hoc analyses examined confounding effects that may have contributed to lack of separation in pain freedom, including site outlier analyses, and results are reported next.

**Identification of outlier site**

Based on the procedure outlined above, one study site met outlier criteria, with a mean 2-hour pain freedom placebo response rate of 75% (Cook's distance, 0.8). At all other sites, the mean 2-hour pain freedom placebo response rate was 23.5% (Supplemental Fig. 1). This site, which included 12 patients treated with placebo and 15 patients treated with celecoxib oral solution, was therefore excluded from efficacy analyses in the results presented below. The Supplemental Appendix to this document provides all efficacy analyses with the outlier site included.

**Co-primary efficacy endpoints with outlier site removed**

For the co-primary endpoint of headache pain freedom at 2 hours post-dose, response rates (LOCF, 95% CI) in the celecoxib oral solution group were higher (32.8% [27.2%, 38.8%] than placebo (23.5% [18.5%, 29.2%]), with statistically significant differences (using Fisher’s exact test) between treatment groups \((P=\)
0.020) in favor of celecoxib oral solution (Table 2). For the co-primary endpoint of 2-hour MBS freedom, response rates (LOCF, 95% CI) in the celecoxib oral solution group were higher (58.1% [51.4%, 64.5%]) than placebo (43.9% [37.2%, 50.7%]), with statistically significant differences between treatment groups ($P = 0.003$) in favor of celecoxib oral solution (Table 2).

Table 2

<table>
<thead>
<tr>
<th>Headache pain freedom at 2 hours post-dose</th>
<th>Placebo n = 268</th>
<th>Celecoxib oral solution n = 272</th>
<th>Placebo n = 268</th>
<th>Celecoxib oral solution n = 272</th>
</tr>
</thead>
<tbody>
<tr>
<td>LOCF</td>
<td>Observed</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Headache pain freedom at 2 hours post-dose</td>
<td>255</td>
<td>265</td>
<td>246</td>
<td>260</td>
</tr>
<tr>
<td>Number of responses</td>
<td>60</td>
<td>87</td>
<td>56</td>
<td>84</td>
</tr>
<tr>
<td>Proportion (95% CI), %</td>
<td>23.5 (18.5, 29.2)</td>
<td>32.8 (27.2, 38.8)</td>
<td>22.8 (17.7, 28.5)</td>
<td>32.3 (26.7, 38.4)</td>
</tr>
<tr>
<td>$P$-value</td>
<td>-</td>
<td>0.020</td>
<td>-</td>
<td>0.017</td>
</tr>
</tbody>
</table>

**Absence of screening MBS at 2 hours post-dose**

<table>
<thead>
<tr>
<th>Absence of screening MBS at 2 hours post-dose</th>
<th>Placebo n = 268</th>
<th>Celecoxib oral solution n = 272</th>
<th>Placebo n = 268</th>
<th>Celecoxib oral solution n = 272</th>
</tr>
</thead>
<tbody>
<tr>
<td>Assessments at 2 hours post-dose, n</td>
<td>221</td>
<td>229</td>
<td>214</td>
<td>224</td>
</tr>
<tr>
<td>Number of responses</td>
<td>97</td>
<td>133</td>
<td>93</td>
<td>129</td>
</tr>
<tr>
<td>Proportion (95% CI), %</td>
<td>43.9 (37.2, 50.7)</td>
<td>58.1 (51.4, 64.5)</td>
<td>43.5 (36.7, 50.4)</td>
<td>57.6 (50.8, 64.1)</td>
</tr>
<tr>
<td>$P$-value</td>
<td>-</td>
<td>0.003</td>
<td>-</td>
<td>0.004</td>
</tr>
</tbody>
</table>

CI, confidence interval; LOCF, last observation carried forward; MBS, most bothersome symptom.

†Analysis excludes outlier site.

**Secondary endpoints with outlier site removed**

The change from baseline in treatment satisfaction, as measured by the PPMQ-R at 24 hours post-dose, was higher for celecoxib oral solution compared with placebo in total score ($P = 0.006$), total raw score ($P = 0.003$), the subscales of efficacy ($P = 0.003$) and function ($P = 0.007$), the global item of medication effectiveness ($P = 0.002$), and overall satisfaction ($P = 0.010$). For celecoxib oral solution patients only, the comparison between 24-hours post-dose PPMQ-R and baseline PPMQ-R (patients’ pre-study usual migraine medication) showed significantly greater satisfaction compared with baseline in total score ($P =$
In terms of freedom from migraine symptoms (nausea, photophobia, and phonophobia), freedom from photophobia response was significantly greater for celecoxib oral solution patients at 1.5 ($P = 0.013$), 2 ($P = 0.001$), and 4 hours post-dose ($P = 0.005$). Freedom from phonophobia response was significantly greater for patients receiving celecoxib oral solution at 1.5 hours ($P = 0.030$) and 2 hours post-dose ($P = 0.019$). Freedom from nausea was significantly greater for patients receiving celecoxib oral solution at 4 hours ($P = 0.046$) (Fig. 2).

For headache pain relief at 2 hours post-dose, 180/265 (67.9%) celecoxib oral solution patients experienced headache pain relief compared with 141/255 (55.3%) placebo patients ($P = 0.004$) (Fig. 3). For headache pain relief at timepoints other than the 2-hour post-dose, the percentage of celecoxib oral solution responders was greater than the placebo group at all timepoints beyond 15 minutes post-dose, with statistical significance seen at 1 hour (celecoxib oral solution: 129/264 [48.9%] versus placebo: 96/249 [38.6%]; $P = 0.021$), 1.5 hours (celecoxib oral solution: 155/265 [58.5%] versus placebo: 119/250 [47.6%]; $P = 0.014$), and 4 hours post-dose (celecoxib oral solution: 219/266 [82.3%] versus placebo: 189/259 [73.0%]; $P = 0.012$). Finally, the percentage of celecoxib oral solution patients with sustained headache pain relief from 2 to 24 hours post-dose was higher (58.3%) than the placebo group (42.8%; $P = 0.002$).

Subgroup analyses for age, sex, and ethnicity did not reveal any impact to reported efficacy results.

**Safety and tolerability**

Thirty-one of 289 (10.7%) celecoxib oral solution patients and 28 of 283 (9.9%) placebo patients reported a treatment-emergent AE (TEAE). Study-drug-related TEAEs were reported by 21/289 (7.3%) celecoxib oral solution patients and 21/283 (7.4%) placebo patients. The most commonly reported TEAEs were nausea (4 [1.4%] celecoxib oral solution patients and 5 [1.8%] placebo patients) and dysgeusia (5 [1.7%] celecoxib oral solution patients and 3 [1.1%] placebo patients). No study-drug-related TEAEs were reported by ≥ 2.0% of patients, and no deaths occurred during the study. There were no treatment-emergent serious AEs (SAEs); 4 non-treatment-emergent SAEs were reported in 3 patients. Three patients (all placebo) discontinued the study due to a TEAE, while 3 patients (2 placebo, 1 celecoxib oral solution) discontinued the study after experiencing AEs unrelated to the study drug.

Overall, there were no clinically meaningful changes from baseline for any clinical laboratory variables, vital statistics, or ECG readings, and no new safety signals were identified.

**Discussion**

In this randomized, placebo-controlled trial of patients with moderate-to-severe episodic migraine, celecoxib oral solution achieved statistically significant results for the co-primary efficacy endpoints of freedom from headache pain and MBS at 2 hours (32.8%, vs 23.5%; $P = 0.020$, and 58.1% vs 43.9%; $P = 0.005$), total raw score ($P = 0.018$), and the subscales of function ($P < 0.001$), ease of use ($P = 0.014$), tolerability ($P < 0.001$), and the global item of side effects ($P = 0.001$).
These results were obtained after excluding an outlier site with disproportionate placebo response from the analysis. Prior to this exclusion, 2-hour pain freedom response rates were essentially unchanged for celecoxib oral solution (32.9%), but rose to 25.8% for placebo, and no statistically significant difference was observed between treatment groups ($P = 0.075$). Removal of the outlier site did not change the statistical significance of the MBS analysis: with the outlier site, 58.9% of patients receiving celecoxib oral solution reported MBS freedom, compared to 45.0% of placebo patients ($P = 0.003$).

Response for celecoxib oral solution was significantly higher than placebo for many secondary endpoints, including: treatment satisfaction (7-point scale at 2 and 4 hours and PPMQ-R at 24 hours post-dose); headache pain relief, including a significant response as early as 1 hour post-dose; freedom from the migraine symptoms of photophobia and phonophobia; and sustained headache pain relief.

No safety signals were identified during the study, and celecoxib oral solution was well tolerated, with 31/289 (10.7%) patients reporting a TEAE, and 21 (7.3%) experiencing a TEAE considered related to the study drug. Notably, the incidence of GI-related TEAEs was low; for example, nausea occurred in 4 (1.4%) patients taking celecoxib oral solution versus 5 (1.8%) placebo patients. There were no deaths or treatment-emergent SAEs, although 4 non-treatment-emergent SAEs were reported. Three patients (0.5%, all placebo) discontinued due to a TEAE, and 3 patients (2 placebo, 1 celecoxib oral solution) had non-treatment-emergent AEs, leading to study drug discontinuation.

These findings support results from the first randomized, placebo-controlled efficacy and safety trial of celecoxib oral solution. Among patients treated with celecoxib oral solution, 35.6% experienced freedom from migraine pain at 2 hours ($P<0.001$ vs placebo), with a low incidence of GI TEAEs (nausea occurred in 9 [3.2%] celecoxib oral solution and 5 [1.8%] placebo patients) [26]. The current study similarly found that approximately one-third of patients treated with celecoxib oral solution reported pain freedom at 2 hours, alongside a very low incidence of gastric TEAEs that was similar for active treatment and placebo.

Also noteworthy to this study is that approximately one-half of patients receiving celecoxib oral solution reported headache pain relief at 1-hour post-dose. The potential for rapid pain relief with celecoxib oral solution is congruent with its pharmacology: celecoxib oral solution 120 mg reaches peak concentrations within 0.7 hours, giving it a more rapid onset of action than celecoxib capsules 400 mg capsules ($T_{max}$ 2.5 hours) [28]. Considered jointly, this information suggests that celecoxib oral solution may provide effective acute therapy for patients requiring rapid relief from migraine pain. This finding will need to be evaluated in greater depth using comparative research.

Last, the current results support existing research showing that NSAIDs are effective in migraine [1], and that COX-2-specific NSAIDs can address inflammation and pain while sparing patients from COX-1-mediated AEs [20].

Strengths and limitations
The strengths of this study include the large number of patients and the study design itself. Patients used eDiaries to immediately record real-time data regarding migraine attack severity; the impact of treatment on migraine pain, bothersome symptoms, and functional disability; treatment satisfaction; and rescue medication use. Therefore, investigators were able to rapidly assess the effects of celecoxib oral solution at multiple timepoints, and as early as 15 minutes.

Study limitations include a high placebo response and the lack of a direct comparator arm (for example, commercially available celecoxib capsules).

**Conclusions**

Celecoxib oral solution is a safe, effective COX-2-selective NSAID approved in the U.S. for acute migraine relief. Treatment with celecoxib oral solution is associated with a low incidence of gastric adverse events, and may provide a convenient, alternate option to triptans, non-selective NSAIDs, and currently available celecoxib capsule formulations.

**List Of Abbreviations**

AE: Adverse event  
ALT: Alanine aminotransferase  
AST: Aspartate aminotransferase  
BMI: Body mass index  
CI: Confidence interval  
COX: Cyclooxygenase  
CYP: Cytochrome P450  
DB: Double-blind  
DBP: Diastolic blood pressure  
DFN-15: Celecoxib oral solution, 25 mg/mL  
ECG: Electrocardiogram  
eDiary: Electronic diary  
FAS: Full analysis set  
GI: Gastrointestinal
Declarations

Ethics approval and consent to participate: The research protocol, patient information and informed consent form, and other relevant study documentation were reviewed and approved by the Institutional Review Boards for each study center.

Consent for publication: Not applicable.

Availability of data and materials:

The datasets generated and/or analyzed during the current study are not publicly available due but are available from the corresponding author on reasonable request.

Competing interests:

RBL has received research support from the NIH. He also receives support from the Migraine Research Foundation and the National Headache Foundation. He serves on the editorial board of Neurology, senior advisor to Headache, and associate editor to Cephalalgia. He has reviewed for the NIA and NINDS, holds stock options in eNeura Therapeutics and Biohaven Holdings; serves as consultant, advisory board member, or has received honoraria from: American Academy of Neurology, Allergan, American Headache

SM is an employee of Dr. Reddy’s Laboratories and owns stock in the company.

SJT received grants for research (no personal compensation) from Allergan/Abbvie, Amgen, Eli Lilly, Lundbeck, Neurolief, Novartis, Satsuma, and Zosano; served as a consultant and/or on advisory boards (honoraria) for Aeon, Allergan/Abbvie, Alphasights, Amgen, Atheneum, Axsome Therapeutics, Becker Pharmaceutical Consulting ClearView Healthcare Partners, CoolTech, CRG, Currax, DRG, Eli Lilly, ExpertConnect, FCB Health, GLG, Guidepoint Global, Health Science Communications, HMP Communications, Impel, InteractiveForums, Krog and Partners, Lundbeck, M3 Global Research, MJH Holdings, Neurolief, Novartis, Palion Medical, Pulmatrix, SAI MedPartners, Satsuma, Spherix Global Insights, Strategy Inc, System Analytic, Taylor and Francis, Teva, Theranica, Unity HA, XOC, and Zosano; received salary from Dartmouth-Hitchcock Medical Center, American Headache Society, Thomas Jefferson University; and received CMR honoraria from American Academy of Neurology, American Headache Society, Catamount Medical Education, Diamond Headache Clinic, Forefront Collaborative, Haymarket Medical Education, Peerview, Medical Education Speakers Network, Migraine Association of Ireland, North American Center for CME, The Ohio State University, Physicians’ Education Resource, PlatformQ Education, Primed, Texas Neurological Society, and WebMD/Medscape.

CI was a paid consultant of Dr. Reddy’s Laboratories.

DS was a paid consultant of Dr. Reddy’s Laboratories.

The authors report no other conflicts of interest related to this work.

**Funding.** Dr. Reddy’s Laboratories, Ltd (Basel, Switzerland) provided funding for independent third-party data collection, analysis of the data, and editorial assistance.

**Authors’ contributions.**

Study authors contributed the following: Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work (RBL, SM, SJT, CI, DS); and, drafting the work or revising it critically for important intellectual content (RBL, SM, SJT); and, final approval of the version to be published (RBL, SM, SJT); and, agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved (RBL, SM, SJT, CI, DS).

**Acknowledgements:** The authors would also like to thank Preeti Singh, MD (Medical Affairs at Promius) for project management and manuscript review and Caitlin Rothermel, MPH (HLG Health Communications) for medical writing and editorial support.
References


March 8, 2021.


**Figures**

**Figure 1**

Participant Disposition
Figure 2

Freedom From Nausea, Photophobia, and Phonophobia at Prespecified Timepoints Post-dose Using LOCF, FAS† FAS, full analysis set; LOCF, last observation carried forward; Pbo, placebo. †Analysis excludes outlier site. *Denotes statistical significance
Figure 3

Proportion of Patients With Headache Pain Relief by Post-dose Timepoint Using LOCF, FAS† LOCF, last observation carried forward. †Analysis excludes outlier site.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- Additionalfile1SupplementalAppendixwithoutbrackets.docx